Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Fizazi, K; Piulats, JM; Reaume, MN; Ostler, P; McDermott, R; Gingerich, JR; Pintus, E; Sridhar, SS; Bambury, RM; Emmenegger, U; Lindberg, H; Morris, D; Nolè, F; Staffurth, J; Redfern, C; Sáez, MI; Abida, W; Daugaard, G; Heidenreich, A; Krieger, L; Sautois, B; Loehr, A; Despain, D; Heyes, CA; Watkins, SP; Chowdhury, S; Ryan, CJ; Bryce, AH

Fizazi, K (通讯作者)，Paris Saclay Univ, Gustave Roussy Inst, 14 Rue Edouard Vaillant, F-94805 Villejuif, France.

NEW ENGLAND JOURNAL OF MEDICINE, 2023; 388 (8): 719

Abstract

BACKGROUND In a phase 2 study, rucaparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), showed a high level of activity in patients who had meta......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索